Segment featuring Dr. Charles Lapp, ME/CFS Key Opinion Leader and founder of the Hunter-Hopkins Center is now available here
OCALA, Fla., Dec. 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the release of a Virtual Investor KOL Connect segment featuring Dr. Charles Lapp, AIM’s Consulting Medical Officer. Dr. Lapp is also the founder of the Hunter-Hopkins Center in Charlotte, N.C., and a Key Opinion Leader who has been treating Chronic Fatigue Syndrome and Fibromyalgia for over 25 years.
As part of the segment, Dr. Lapp discussed results from AIM’s Phase 2 study evaluating the efficacy and safety of Ampligen® as a potential therapeutic for people with the Post-COVID condition of fatigue (“AMP-518”; NCT05592418).
The Virtual Investor KOL Connect Segment can be accessed here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
